-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, with the advancement of a series of favorable pharmaceutical innovation policies, the influx of talents and the increase of capital, China’s biomedicine field has ushered in vigorous development.
More and more local innovative pharmaceutical companies have risen rapidly, and at the same time, the approval of new drugs has been accelerated.
Against the background of the current situation, the pace of launching domestically-made innovative drugs has been greatly accelerated
.
However, compared with multinational pharmaceutical companies, insufficient product commercialization capabilities are a major shortcoming of local innovative pharmaceutical companies
.
In order to make up for this shortcoming, "strong cooperation" is becoming an important driving force for the commercialization of innovative drugs for local pharmaceutical companies
.
Recently, Hua Medicine signed a strategic supply chain cooperation agreement with Sinopharm Holdings on September 13.
The two parties will carry out in-depth cooperation in logistics and warehousing, supply chain management and channel informatization, and jointly promote Hua Medicine’s first-in-class new drugs.
The commercialization process of the glucokinase activator "Dopagliflozin" after it was approved for marketing in China
.
Doxagliptin is a diabetes treatment drug.
It has a new treatment mechanism that is different from traditional diabetes treatment, that is, a brand-new concept of "repair sensing, rebuild homeostasis, and treat diabetes from the source".
It is understood that Hua Medicine is in clinical practice.
The test effectively solved the problem of insulin prime secretion imbalance and realized the steady-state regulation of human blood sugar.
On the basis of effective blood sugar control, it brought new curative effects of continuous improvement of β cell function and insulin resistance
.
The number of diabetic patients in China is huge.
Data shows that the number of patients in 2019 has exceeded 110 million, and it is showing a severe trend of rapid growth
.
The industry believes that the innovative drug will have far-reaching significance for the treatment of diabetes, helping patients in China and the world to curb the occurrence and development of diabetes and its complications
.
It is reported that Hua Medicine submitted the NDA application for the drug in March 2021 and was accepted by the NMPA on April 23
.
The 2021 interim report shows that in promoting the commercialization process, in addition to cooperating with CMO, the company will also set up a production base of Hua Medicine in the Lingang New Area of Shanghai to ensure sufficient commercial supply of Dopagliflozin
.
It is understood that Lingang Life Blue Bay is one of Shanghai’s key biomedical characteristic industrial parks.
The industrial scale is expected to exceed 50 billion yuan in 2025 and 200 billion yuan in 2035.
.
This cooperation will be another development that Hua Medicine has made in the process of commercialization
.
According to the agreement, Sinopharm will take advantage of its nationwide channel network and supply chain resources to provide professional medical logistics services for Hualing; and Sinopharm will rely on Sinopharm’s national drug distribution network to manage its supply chain, etc.
On this basis, the two parties will also expand the possibility of further in-depth cooperation in channel informatization and other aspects
.
According to public information, Sinopharm Holdings includes two A-share listed companies, Sinopharm and Sinopharm Accord.
There are more than 1,000 subsidiary companies.
They are distributors and retailers of Chinese pharmaceuticals, healthcare products, medical devices, and large-scale supply chain services.
Provider
.
In the future, the company plans to deepen the exploration of innovative business models such as "integration of batch and retail", "pharmaceutical equipment linkage", and "zero equipment linkage" to improve the accessibility and convenience of the high-quality medical equipment supply chain and pharmaceutical services, and at the same time improve the synergy of business resources Capabilities, further strengthen the matching and coordination of network resources among various business types and regions, explore business management and control model innovation, and accelerate the promotion of supply chain network integration and service standardization upgrades
.
More and more local innovative pharmaceutical companies have risen rapidly, and at the same time, the approval of new drugs has been accelerated.
Against the background of the current situation, the pace of launching domestically-made innovative drugs has been greatly accelerated
.
However, compared with multinational pharmaceutical companies, insufficient product commercialization capabilities are a major shortcoming of local innovative pharmaceutical companies
.
In order to make up for this shortcoming, "strong cooperation" is becoming an important driving force for the commercialization of innovative drugs for local pharmaceutical companies
.
Recently, Hua Medicine signed a strategic supply chain cooperation agreement with Sinopharm Holdings on September 13.
The two parties will carry out in-depth cooperation in logistics and warehousing, supply chain management and channel informatization, and jointly promote Hua Medicine’s first-in-class new drugs.
The commercialization process of the glucokinase activator "Dopagliflozin" after it was approved for marketing in China
.
Doxagliptin is a diabetes treatment drug.
It has a new treatment mechanism that is different from traditional diabetes treatment, that is, a brand-new concept of "repair sensing, rebuild homeostasis, and treat diabetes from the source".
It is understood that Hua Medicine is in clinical practice.
The test effectively solved the problem of insulin prime secretion imbalance and realized the steady-state regulation of human blood sugar.
On the basis of effective blood sugar control, it brought new curative effects of continuous improvement of β cell function and insulin resistance
.
The number of diabetic patients in China is huge.
Data shows that the number of patients in 2019 has exceeded 110 million, and it is showing a severe trend of rapid growth
.
The industry believes that the innovative drug will have far-reaching significance for the treatment of diabetes, helping patients in China and the world to curb the occurrence and development of diabetes and its complications
.
It is reported that Hua Medicine submitted the NDA application for the drug in March 2021 and was accepted by the NMPA on April 23
.
The 2021 interim report shows that in promoting the commercialization process, in addition to cooperating with CMO, the company will also set up a production base of Hua Medicine in the Lingang New Area of Shanghai to ensure sufficient commercial supply of Dopagliflozin
.
It is understood that Lingang Life Blue Bay is one of Shanghai’s key biomedical characteristic industrial parks.
The industrial scale is expected to exceed 50 billion yuan in 2025 and 200 billion yuan in 2035.
.
This cooperation will be another development that Hua Medicine has made in the process of commercialization
.
According to the agreement, Sinopharm will take advantage of its nationwide channel network and supply chain resources to provide professional medical logistics services for Hualing; and Sinopharm will rely on Sinopharm’s national drug distribution network to manage its supply chain, etc.
On this basis, the two parties will also expand the possibility of further in-depth cooperation in channel informatization and other aspects
.
According to public information, Sinopharm Holdings includes two A-share listed companies, Sinopharm and Sinopharm Accord.
There are more than 1,000 subsidiary companies.
They are distributors and retailers of Chinese pharmaceuticals, healthcare products, medical devices, and large-scale supply chain services.
Provider
.
In the future, the company plans to deepen the exploration of innovative business models such as "integration of batch and retail", "pharmaceutical equipment linkage", and "zero equipment linkage" to improve the accessibility and convenience of the high-quality medical equipment supply chain and pharmaceutical services, and at the same time improve the synergy of business resources Capabilities, further strengthen the matching and coordination of network resources among various business types and regions, explore business management and control model innovation, and accelerate the promotion of supply chain network integration and service standardization upgrades
.
